Statistics

Letter to the Editor

Why choose cyclosporin A as first-line therapy in COVID-19 pneumonia

¿Por qué elegir ciclosporina A como primera línea terapéutica para la neumonía causada por COVID-19?

Olga Sanchez-Pernautea,

Corresponding author

osanchez@fjd.es

Corresponding author.

, Fredeswinda I. Romero-Buenoa, Albert Selva-O’Callaghanb

a Rheumatology Division, Jiménez Díaz Foundation University Hospital and Health Research Institute, Universidad Autónoma de Madrid, Madrid, Spain

b Department of Internal Medicine, Hospital Universitari Val d’Hebron, Universitat Autonoma de Barcelona, Barcelona, Spain

Read

13606

Times
was read the article

1754

Total PDF

11690

Total HTML

162

Total EPUB

Share statistics

Article information

ISSN: 1699258X
Original language: English

The statistics are updated each day

Year/Month	Html	Pdf	Epub	Total

2023 March	105	30	12	147
2023 February	99	32	11	142
2023 January	98	17	4	119
2022 December	133	45	12	190
2022 November	98	42	14	154
2022 October	116	39	12	167
2022 September	111	46	17	174
2022 August	103	55	17	175
2022 July	114	48	22	184
2022 June	113	52	17	182
2022 May	131	63	18	212
2022 April	144	17	1	162
2022 March	175	25	1	201
2022 February	155	23	1	179
2022 January	248	39	0	287
2021 December	299	36	1	336
2021 November	357	29	0	386
2021 October	183	35	0	218
2021 September	146	34	0	180
2021 August	178	23	0	201
2021 July	230	40	0	270
2021 June	224	30	0	254
2021 May	407	37	0	444
2021 April	1011	84	0	1095
2021 March	499	54	0	553
2021 February	742	83	0	825
2021 January	381	51	0	432
2020 December	438	52	0	490
2020 November	520	51	0	571
2020 October	299	43	0	342
2020 September	262	63	0	325
2020 August	343	52	0	395
2020 July	577	66	0	643
2020 June	805	100	0	905
2020 May	1758	197	2	1957
2020 April	88	21	0	109

Show all

Subscribe to our newsletter